LQDA · Liquidia Corporation · Stock research

Current Thesis

The break level named in the prior note came and went. On 2026-08-21 LQDA closed the week at $68.62, through the $70 July shelf and below the post-print low close of $72.10 set on 2026-08-13. That is the second leg of a rejection that began with the 2026-08-12 Q2 print — a quarter that was, on the operating numbers, the best the company has reported: YUTREPIA net product sales $170.4M, +31% sequential off Q1's $129.9M, total revenue $171.7M, net income $74.7M ($0.84 basic / $0.74 diluted), cash $284.2M at 6/30/26 against $190.7M at 12/31/25. Six houses moved targets into $90–$111 across 08-12 and 08-13 — Raymond James went to $106 from $68 (Strong Buy, 08-13), BTIG $111, Needham $110, Wells Fargo $108, BofA $92, and LifeSci Capital cut to Market Perform at $90. None of it produced a bid. The three-month price change has compressed from +30.8% as measured on 2026-08-14 to +12.5% on 2026-08-21, and the shares now sit -24.6% from the $91.03 52-week high with RSI(14) at 32.2. The commercial ramp and the equity narrative have decoupled; the undated '327 bench ruling from Judge Andrews (D. Del. 1:23-cv-00975, PH-ILD only) remains the one event that can re-rate either direction, and it has no calendar entry.

Bullish and bearish views on Liquidia Corporation

The model's bull view on Liquidia Corporation (LQDA), in brief: The growth line has not bent. Q2'26 YUTREPIA net product sales $170.4M, +31% QoQ; management said on the 2026-08-12 call that YUTREPIA's growth alone exceeded growth of the entire inhaled prostacyclin category, with share approaching 30% of that market by net revenue. Patient… The bear view: Every bounce has been sold within two sessions. Both cases follow in full.

Bull Case

• The growth line has not bent. Q2'26 YUTREPIA net product sales $170.4M, +31% QoQ; management said on the 2026-08-12 call that YUTREPIA's growth alone exceeded growth of the entire inhaled prostacyclin category, with share approaching 30% of that market by net revenue.
• Patient base is a counted number. Approximately 5,900 unique patient prescriptions and more than 5,000 patients treated from the June 2025 launch through 2026-07-31, disclosed with Q2 results.
• Funded from operations. Cash and equivalents $284.2M at 2026-06-30, +$61.4M on the quarter, with no issuance required to carry the launch.
• The Street's numbers went up while the price went down. Average target of $98.08 across a book of 1 Strong Buy, 5 Buy, 3 Hold and 2 Sell as tabulated 2026-08-22; management reiterated >$1B net revenue in 2027 on the Q2 call.
• The legal tail narrowed before it widened. Full FDA approval (2025-05-23, PAH and PH-ILD) is independent of '327, which reads on PH-ILD only; the 2026-06-04 SCOTUS decision in Hikma v. Amarin raised the induced-infringement bar for skinny labels.

Bear Case

• Every bounce has been sold within two sessions. Shares rose 4.3% to $77.70 on 2026-08-17, fell 5.8% to $71.05 on 2026-08-20, and closed $68.62 on 2026-08-21. A rally attempt inside a target cluster of $90–$111 that fails in three days says the marginal buyer was already positioned into the print.
• Insiders sold into the drawdown. Form 4 activity reported 2026-08-22 shows Chief Medical Officer Rajeev Saggar selling 29,534 shares at an average $76.84 on 2026-08-17 and 50,000 shares at an average $74.06 on 2026-08-19, leaving 142,265 shares. GuruFocus, summarising the trailing three months as of 2026-08-20, put insider sales at $160.2M against $0.3M of buying.
• Single molecule, undated injunction risk. YUTREPIA was $170.4M of $171.7M in Q2 revenue. Management told the Q2 call it has no visibility into Judge Andrews' timeline and that an adverse outcome could produce royalties or injunctive relief.
• The earnings line bends in H2. R&D spend was guided to double in H2 2026 across ten studies underway or planned within twelve months, so the $74.7M quarterly net income is not a run-rate to extrapolate.
• No dated catalyst for roughly eleven weeks. Q1 printed 2026-05-11, Q2 on 2026-08-12; the next scheduled disclosure is a Q3 report around 2026-11-10. Between now and then the only scheduled flow is index and sector beta.

Setup & Price Structure

Reference close $68.62 (2026-08-21), -24.6% from the $91.03 52-week high, RSI(14) 32.2. The July breakout shelf at $70 is gone; the 2026-08-13 post-print low close of $72.10 is gone; the 2026-08-17 recovery to $77.70 lasted two sessions. Price sits below all six post-print targets and below the $98.08 average. Positioning observables, stated as observables: institutional ownership 64.54% (2026-08-22 tabulation), S&P SmallCap 600 membership since 2026-06-22 so a portion of daily volume is index-driven, and two insider sales in the week ended 08-21 at $74–$77 while the stock was falling. RSI in the low 30s with no dated event inside 30 days is an oversold reading without a scheduled reason to resolve.

The narrative is dead. Dated by the 2026-08-21 weekly close of $68.62, which broke the shelf the July advance was built on, and by the failure of six target actions on 08-12/08-13 to attract a bid. This label is about the price narrative, not the P&L: the operating story is still compounding at +31% sequential. What died is the re-rating leg — the market has stopped paying up for each incremental sales datapoint. A new leg requires a new fact, and the two candidates ('327, Q3 sales) are one undated and one eleven weeks out.

Catalyst Calendar (next 30 days)

• No scheduled company catalyst between 2026-08-23 and 2026-09-22. The Q2 8-K landed 2026-08-12; the Q3 report is expected around ~2026-11-10 (est.) on the pattern of 05-11 and 08-12 prints.
• ~2026-11-10 (est.): Q3 FY26 print — first read on whether YUTREPIA clears $170.4M and what the doubled H2 R&D does to the net income line.

Elapsed catalysts

• Undated, live in every session: Judge Andrews' '327 bench ruling, D. Del. 1:23-cv-00975. Pending with no disclosed timeline as of the 2026-08-12 call. (passed 14d ago)

What Would Change Our Mind

The structural argument that fails first is sequential growth: Q3 YUTREPIA net sales at or below $170.4M, or inhaled-prostacyclin share stalling below 30% of net revenue, would mean the switch cohort is exhausted and the >$1B 2027 guide is the wrong anchor. Second, a '327 docket entry ordering permanent injunctive relief on PH-ILD rather than damages or an ongoing royalty removes part of the only revenue engine with no notice. On price, a weekly close below $65 would put the shares under the entire May 2026 post-Q1 target cluster ($59–$70 across BTIG, Wells Fargo, HC Wainwright and Needham on 05-11/05-12) and say the market is repricing the 2027 guide rather than digesting a print. In the other direction: a weekly close back above $77.70 (the failed 2026-08-17 high close) with the 08-19/08-20 distribution absorbed, or a damages-only '327 outcome, would put the narrative back into a live phase and make the gap to the $98.08 average target the operative question again.

Correlation Notes

• United Therapeutics is the direct counterweight. YUTREPIA's share gains come out of Tyvaso DPI; UTHR guidance on Tyvaso revenue and retained share at its next print is the cleanest external read on whether the ramp converts to net revenue or to gross-to-net discounting.
• Index beta since 2026-06-22. S&P SmallCap 600 inclusion means part of daily flow tracks small-cap risk appetite rather than company news — relevant when reading a -5.8% session like 2026-08-20 with no company headline attached.
• Sector beta. Single-product commercial-stage biotech trades with the biotech complex on rate and risk moves; the 2026-08-17 to 2026-08-21 path (+4.3%, then -5.8%, then a lower weekly close) ran without a company-specific news item.
• Litigation is idiosyncratic. The '327 ruling is uncorrelated with sector or index flow and can arrive on any docket day, which is why the drawdown carries an event overhang a comparable non-litigating name would not.